Related Experiment Videos

Effect of prostaglandins against alloxan-induced diabetes mellitus

M M Sailaja Devi1, U N Das

  • 1UND Life Sciences, Shaker Heights, OH 44120, USA.

Prostaglandins, Leukotrienes, and Essential Fatty Acids
|November 22, 2005
PubMed

Insights

Certain prostaglandins (PGs) like PGE1, PGE2, PGF1α, and PGF3α protect against alloxan-induced diabetes in rats. These PGs also restore antioxidant levels, suggesting a therapeutic role in managing chemically induced diabetes and oxidative stress.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Pharmacology

Background:

  • Alloxan induces cytotoxicity and apoptosis in rat insulinoma cells.
  • Prostaglandins (PGs) are lipid compounds with diverse physiological roles.
  • Oxidative stress is implicated in the pathogenesis of diabetes mellitus.

Purpose of the Study:

  • To investigate the in vivo protective effects of various prostaglandins against alloxan-induced diabetes mellitus in rats.
  • To determine if prostaglandins can restore antioxidant status in diabetic rats.

Main Methods:

  • Male Wistar rats were administered prostaglandins intraperitoneally prior to alloxan induction.
  • Diabetes mellitus was chemically induced using alloxan.
  • Antioxidant status was assessed in red blood cells and pancreas.

Main Results:

  • Prostaglandin E1 (PGE1), PGE2, PGF1α, and PGF3α significantly prevented alloxan-induced diabetes.
  • Prostaglandin I2 (PGI2), thromboxane B2 (TXB2), and 6-keto-PGF1α were less effective.
  • PGE1, PGE2, PGF1α, and PGF3α restored antioxidant levels in red blood cells and pancreas.

Conclusions:

  • PGE1, PGE2, PGF1α, and PGF3α can abrogate chemically induced diabetes mellitus in experimental models.
  • These prostaglandins attenuate the oxidative stress associated with diabetes mellitus.
  • The findings suggest a potential therapeutic application of these PGs in managing diabetes.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.